COVID-19 in unvaccinated patients with inborn errors of immunity-polish experience.
COVID-19
COVID-19 unvaccinated patients
adults
children
inborn errors of immunity
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
05
2022
accepted:
07
09
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
At the beginning of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, patients with inborn errors of immunity (IEI) appeared to be particularly vulnerable to a severe course of the disease. It quickly turned out that only some IEI groups are associated with a high risk of severe infection. However, data on the course of Coronavirus Disease 2019 (COVID-19) in patients with IEI are still insufficient, especially in children; hence, further analyses are required. The retrospective study included 155 unvaccinated people with IEI: 105 children and 50 adults (67.7% and 32.3%, respectively). Male patients dominated in the study group (94 people, 60.6%). At least two comorbidities were found in 50 patients (32.3%), significantly more often in adults (56% vs. 21%). Adult patients presented significantly more COVID-19 symptoms. Asymptomatic and mildly symptomatic course of COVID-19 was demonstrated in 74.8% of the entire group, significantly more often in children (88.6% vs. 46%). Moderate and severe courses dominated in adults (54% vs. 11.4%). Systemic antibiotic therapy was used the most frequently, especially in adults (60% vs. 14.3%). COVID-19-specific therapy was used almost exclusively in adults. In the whole group, complications occurred in 14.2% of patients, significantly more often in adults (30% vs. 6.7%). In the pediatric group, there were two cases (1.9%) of multisystem inflammatory syndrome in children. Deaths were reported only in the adult population and accounted for 3.9% of the entire study group. The death rate for all adults was 12%, 15.4% for adults diagnosed with common variable immunodeficiency, 12.5% for those with X-linked agammaglobulinemia, and 21.4% for patients with comorbidity. The results of our study imply that vaccinations against COVID-19 should be recommended both for children and adults with IEI. Postexposure prophylaxis and early antiviral and anti-SARS-CoV-2 antibody-based therapies should be considered in adults with IEI, especially in those with severe humoral immune deficiencies and comorbidity.
Identifiants
pubmed: 36211407
doi: 10.3389/fimmu.2022.953700
pmc: PMC9537609
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
953700Informations de copyright
Copyright © 2022 Kołtan, Ziętkiewicz, Grześk, Becht, Berdej-Szczot, Cienkusz, Ewertowska, Heropolitańska-Pliszka, Krysiak, Lewandowicz-Uszyńska, Mach-Tomalska, Matyja-Bednarczyk, Milchert, Napiórkowska-Baran, Pieniawska-Śmiech, Pituch-Noworolska, Renke, Roliński, Rywczak, Stelmach-Gołdyś, Strach, Suchanek, Sulicka-Grodzicka, Szczawińska-Popłonyk, Tokarski, Więsik-Szewczyk, Wolska-Kuśnierz, Zeman and Pac.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4
pubmed: 32333914
Pediatr Allergy Immunol. 2022 Jan;33(1):e13661
pubmed: 34510555
Front Immunol. 2022 Jan 31;13:837243
pubmed: 35173743
Clin Immunol. 2021 Sep;230:108821
pubmed: 34391937
JAMA Netw Open. 2021 Jun 1;4(6):e2116420
pubmed: 34110391
Curr Opin Pediatr. 2021 Dec 1;33(6):648-656
pubmed: 34734915
Clin Exp Immunol. 2022 Sep 29;209(3):247-258
pubmed: 35641155
J Clin Immunol. 2018 Oct;38(7):816-832
pubmed: 30302726
J Clin Immunol. 2021 Feb;41(2):345-355
pubmed: 33263173
J Clin Immunol. 2021 Oct;41(7):1515-1522
pubmed: 34231093
Front Immunol. 2019 Jul 19;10:1272
pubmed: 31379802
Am J Clin Exp Immunol. 2021 Oct 15;10(3):77-85
pubmed: 34824897
J Clin Immunol. 2021 Oct;41(7):1479-1489
pubmed: 34164762
Clin Exp Immunol. 2015 Oct;182(1):45-50
pubmed: 26031847
J Clin Invest. 2021 Jul 15;131(14):
pubmed: 34061775
Front Immunol. 2022 Feb 28;13:835770
pubmed: 35296097
J Allergy Clin Immunol Pract. 2021 Jan;9(1):504-507.e1
pubmed: 33217615
Expert Rev Clin Immunol. 2021 Feb;17(2):163-168
pubmed: 33412960
J Clin Med. 2021 Oct 30;10(21):
pubmed: 34768630
J Allergy Clin Immunol. 2021 Feb;147(2):520-531
pubmed: 32980424
Am J Med Sci. 2020 Dec;360(6):740-741
pubmed: 32773108
J Med Virol. 2021 Mar;93(3):1449-1458
pubmed: 32790106
J Clin Immunol. 2021 Oct;41(7):1463-1478
pubmed: 34114122